

Giuseppe Pantaleo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8929064/publications.pdf>

Version: 2024-02-01

161
papers

15,344
citations

38742

50
h-index

18647

119
g-index

174
all docs

174
docs citations

174
times ranked

14181
citing authors

#	ARTICLE	IF	CITATIONS
1	High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus. <i>Clinical Microbiology and Infection</i> , 2022, 28, 611.e1-611.e7.	6.0	3
2	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. <i>JAMA Oncology</i> , 2022, 8, e220446.	7.1	48
3	Human macrophages and monocyte-derived dendritic cells stimulate the proliferation of endothelial cells through midkine production. <i>PLoS ONE</i> , 2022, 17, e0267662.	2.5	4
4	Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19. <i>Viruses</i> , 2022, 14, 1089.	3.3	9
5	Antibodies to combat viral infections: development strategies and progress. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 676-696.	46.4	68
6	Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. <i>Journal of Virology</i> , 2021, 95, .	3.4	200
7	Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab149.	0.9	18
8	Acquisition of optimal TFH cell function is defined by specific molecular, positional, and TCR dynamic signatures. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	11
9	A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial. <i>Journal of Virology</i> , 2021, 95, .	3.4	6
10	Implementing SARS-CoV-2 Rapid Antigen Testing in the Emergency Ward of a Swiss University Hospital: The INCREASE Study. <i>Microorganisms</i> , 2021, 9, 798.	3.6	51
11	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , 2021, 6, 56.	6.0	7
12	Case Report: SARS-CoV-2 as an unexpected causal agent of isolated febrile hepatitis. <i>F1000Research</i> , 2021, 10, 400.	1.6	1
13	Case Report: A Rare Truncating Variant of the CFHR5 Gene in IgA Nephropathy. <i>Frontiers in Genetics</i> , 2021, 12, 529236.	2.3	3
14	Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	34
15	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e049232.	1.9	10
16	Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports. <i>Frontiers in Medicine</i> , 2021, 8, 663258.	2.6	2
17	A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	68
18	The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. <i>Nature Communications</i> , 2021, 12, 4888.	12.8	67

#	ARTICLE	IF	CITATIONS
19	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. <i>Nature Communications</i> , 2021, 12, 5215.	12.8	22
20	A highly potent antibody effective against SARS-CoV-2 variants of concern. <i>Cell Reports</i> , 2021, 37, 109814.	6.4	39
21	Reactivation of IgA vasculitis after COVID-19 vaccination. <i>Lancet Rheumatology</i> , The, 2021, 3, e617.	3.9	54
22	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. <i>PLoS Pathogens</i> , 2021, 17, e1010016.	4.7	1
23	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. <i>Clinical Infectious Diseases</i> , 2020, 72, 50-60.	5.8	15
24	The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet</i> , The, 2020, 395, 384-388.	13.7	44
25	Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA. <i>Viruses</i> , 2020, 12, 973.	3.3	8
26	Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. <i>PLoS Pathogens</i> , 2020, 16, e1008522.	4.7	11
27	In Situ Characterization of Follicular Helper CD4 T Cells Using Multiplexed Imaging. <i>Frontiers in Immunology</i> , 2020, 11, 607626.	4.8	12
28	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	8.4	8
29	TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice. <i>PLoS Pathogens</i> , 2020, 16, e1009025.	4.7	19
30	Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement. <i>PLoS Pathogens</i> , 2019, 15, e1007918.	4.7	16
31	Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. <i>Lancet HIV</i> , the, 2019, 6, e334-e340.	4.7	5
32	Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion. <i>BMC Biotechnology</i> , 2019, 19, 67.	3.3	15
33	Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01. <i>Cell Host and Microbe</i> , 2019, 26, 623-637.e8.	11.0	56
34	Safety and tolerance of lymph node biopsies from chronic HIV-1 volunteers in rural Tanzania. <i>BMC Research Notes</i> , 2019, 12, 561.	1.4	0
35	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , the, 2019, 6, e737-e749.	4.7	43
36	Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption. <i>PLoS ONE</i> , 2019, 14, e0210965.	2.5	8

#	ARTICLE	IF	CITATIONS
37	Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. <i>Journal of Experimental Medicine</i> , 2019, 216, 1525-1541.	8.5	23
38	SAT0205...A CYTOKINE "SCAR SIGNATURE" CHARACTERIZES PATIENTS WITH FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND SJOGREN'S SYNDROME. , 2019, , .		0
39	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	18
40	A Robust Method for Assaying the Immunoreactive Fraction in Nonequilibrium Systems. <i>Pharmaceuticals</i> , 2019, 12, 177.	3.8	8
41	T-cell exhaustion in HIV infection. <i>Immunological Reviews</i> , 2019, 292, 149-163.	6.0	217
42	Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses. <i>Frontiers in Immunology</i> , 2019, 10, 2941.	4.8	9
43	Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. <i>PLoS ONE</i> , 2019, 14, e0225622.	2.5	20
44	Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Antisense Protein (ASP) RNA Transcripts in Patients by Strand-Specific RT-PCR. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	3
45	HIV Infection Functionally Impairs Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses. <i>Journal of Virology</i> , 2019, 93, .	3.4	48
46	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. <i>Journal of Virology</i> , 2019, 93, .	3.4	25
47	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. <i>Journal of Virology</i> , 2019, 93, .	3.4	13
48	Comparative analysis and generation of a robust HIV-1 DNA quantification assay. <i>Journal of Virological Methods</i> , 2019, 263, 24-31.	2.1	9
49	Detection of antisense protein (ASP) RNA transcripts in individuals infected with human immunodeficiency virus type 1 (HIV-1). <i>Journal of General Virology</i> , 2019, 100, 863-876.	2.9	15
50	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. <i>Journal of Clinical Investigation</i> , 2019, 129, 4769-4785.	8.2	27
51	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018, 92, .	3.4	46
52	Hyperglycaemia is inversely correlated with live <i>M. bovis</i> BCG-specific CD4 ⁺ T cell responses in Tanzanian adults with latent or active tuberculosis. <i>Immunity, Inflammation and Disease</i> , 2018, 6, 345-353.	2.7	7
53	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	3.4	10
54	Antibodies to <i>Chlamydia trachomatis</i> and reproductive health issues in women with SLE: a case-control study. <i>Lupus Science and Medicine</i> , 2018, 5, e000293.	2.7	0

#	ARTICLE	IF	CITATIONS
55	Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial. <i>Vaccine</i> , 2018, 36, 6163-6169.	3.8	42
56	CD32 ⁺ and PD-1 ⁺ Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals. <i>Journal of Virology</i> , 2018, 92, .	3.4	38
57	TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. <i>Journal of Clinical Investigation</i> , 2018, 128, 4387-4396.	8.2	55
58	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	135
59	Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. <i>Journal of Virology</i> , 2017, 91, .	3.4	29
60	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. <i>Journal of Virology</i> , 2017, 91, .	3.4	26
61	A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles. <i>Virology</i> , 2017, 507, 242-256.	2.4	5
62	Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial. <i>EBioMedicine</i> , 2017, 24, 195-204.	6.1	12
63	Targeted Immune Interventions for an HIV-1 Cure. <i>Trends in Molecular Medicine</i> , 2017, 23, 945-961.	6.7	41
64	The Immunopathogenesis of HIV-1 Infection. , 2017, , 837-845.e3.		1
65	Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005817.	3.0	29
66	Therapeutic vaccines and immunological intervention in HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 576-584.	3.8	40
67	Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation. <i>Human Immunology</i> , 2016, 77, 483-489.	2.4	35
68	PD-1 ⁺ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. <i>Nature Medicine</i> , 2016, 22, 754-761.	30.7	388
69	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. <i>Journal of Virology</i> , 2016, 90, 4133-4149.	3.4	22
70	A case for preART-adjusted endpoints in HIV therapeutic vaccine trials. <i>Vaccine</i> , 2016, 34, 1282-1288.	3.8	11
71	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. <i>PLoS Pathogens</i> , 2015, 11, e1005142.	4.7	445
72	COMPASS identifies T-cell subsets correlated with clinical outcomes. <i>Nature Biotechnology</i> , 2015, 33, 610-616.	17.5	232

#	ARTICLE	IF	CITATIONS
73	NF κ B activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1333-E1342.	7.1	26
74	Interleukin-1- and Type I Interferon-Dependent Enhanced Immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef Vaccine Vector with Dual Deletions of Type I and Type II Interferon-Binding Proteins. Journal of Virology, 2015, 89, 3819-3832.	3.4	10
75	Emerging single-cell technologies in immunology. Journal of Leukocyte Biology, 2015, 98, 23-32.	3.3	19
76	Combined Use of Mycobacterium tuberculosis α €“Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis. Clinical Infectious Diseases, 2015, 60, 432-437.	5.8	75
77	Immune correlates of vaccine protection against HIV-1 acquisition. Science Translational Medicine, 2015, 7, 310rv7.	12.4	179
78	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. Journal of Virology, 2015, 89, 8643-8650.	3.4	42
79	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. Journal of Virology, 2015, 89, 8525-8539.	3.4	35
80	Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles. Journal of Virology, 2015, 89, 970-988.	3.4	30
81	Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. Journal of Experimental Medicine, 2014, 211, 2033-2045.	8.5	108
82	Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 β -chain (CD11a) in MS patients. Multiple Sclerosis Journal, 2014, 20, 837-842.	3.0	15
83	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4 \tilde{A} —: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2014, 14, 291-300.	9.1	100
84	Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. Journal of Experimental Medicine, 2013, 210, 143-156.	8.5	581
85	<i>Mycobacterium tuberculosis</i> α €“specific CD8 ⁺ T cells are functionally and phenotypically different between latent infection and active disease. European Journal of Immunology, 2013, 43, 1568-1577.	2.9	172
86	MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects. Neurological Sciences, 2013, 34, 539-543.	1.9	4
87	Immune response to HIV. Current Opinion in HIV and AIDS, 2013, 8, 1.	3.8	43
88	Vaccine and immunotherapeutic interventions. Current Opinion in HIV and AIDS, 2013, 8, 236-242.	3.8	21
89	Systems biology in the development of HIV vaccines. Current Opinion in HIV and AIDS, 2012, 7, 44-49.	3.8	2
90	The Number of Toll-Like Receptor 9-Agonist Motifs in the Adenovirus Genome Correlates with Induction of Dendritic Cell Maturation by Adenovirus Immune Complexes. Journal of Virology, 2012, 86, 6279-6285.	3.4	25

#	ARTICLE	IF	CITATIONS
91	HLA-B7â€‘Restricted EBV-Specific CD8+ T Cells Are Dysregulated in Multiple Sclerosis. <i>Journal of Immunology</i> , 2012, 188, 4671-4680.	0.8	36
92	Nonrandom Distribution of Cryptic Repeating Triplets of Purines and Pyrimidines (RNY) in gp120 of HIV Type1. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 493-504.	1.1	0
93	Functional Avidity: A Measure to Predict the Efficacy of Effector T Cells?. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-14.	3.3	101
94	NYVAC immunization induces polyfunctional HIVâ€‘specific Tâ€‘cell responses in chronicallyâ€‘infected, ARTâ€‘treated HIV patients. <i>European Journal of Immunology</i> , 2012, 42, 3038-3048.	2.9	30
95	Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTUâ€‘Multi-HIVB, in untreated HIV-1 infected subjects. <i>Vaccine</i> , 2012, 30, 4046-4054.	3.8	36
96	Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C. <i>PLoS ONE</i> , 2012, 7, e35485.	2.5	30
97	Modulation of human memory Tâ€‘cell function by different antigenâ€‘presenting cells. <i>European Journal of Immunology</i> , 2012, 42, 799-802.	2.9	3
98	Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens. <i>PLoS ONE</i> , 2012, 7, e48524.	2.5	30
99	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). <i>Vaccine</i> , 2011, 29, 8309-8316.	3.8	70
100	Dominant TNF-Î±+ Mycobacterium tuberculosisâ€‘specific CD4+ T cell responses discriminate between latent infection and active disease. <i>Nature Medicine</i> , 2011, 17, 372-376.	30.7	380
101	Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7131-7136.	7.1	121
102	DNA/NYVAC Vaccine Regimen Induces HIV-Specific CD4 and CD8 T-Cell Responses in Intestinal Mucosa. <i>Journal of Virology</i> , 2011, 85, 9854-9862.	3.4	35
103	Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors. <i>PLoS ONE</i> , 2011, 6, e18164.	2.5	46
104	Poxvirus vector-based HIV vaccines. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 391-396.	3.8	68
105	Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. <i>Lancet Neurology</i> , The, 2010, 9, 264-272.	10.2	86
106	Cytokine mRNA profile of Epsteinâ€‘Barr virus-stimulated highly differentiated T cells in multiple sclerosis: A pilot study. <i>Journal of Neuroimmunology</i> , 2010, 225, 167-170.	2.3	4
107	Long sequence duplications, repeats, and palindromes in HIV-1 gp120: Length variation in V4 as the product of misalignment mechanism. <i>Virology</i> , 2010, 399, 167-175.	2.4	12
108	Intrathecal immune responses to EBV in early MS. <i>European Journal of Immunology</i> , 2010, 40, 878-887.	2.9	83

#	ARTICLE	IF	CITATIONS
109	Proliferation Capacity and Cytotoxic Activity Are Mediated by Functionally and Phenotypically Distinct Virus-Specific CD8 T Cells Defined by Interleukin-7R α (CD127) and Perforin Expression. <i>Journal of Virology</i> , 2010, 84, 3868-3878.	3.4	46
110	The immunopathogenesis of HIV-1 infection. , 2010, , 944-953.		0
111	The Polymorphic Nature of HIV Type 1 env V4 Affects the Patterns of Potential N-Glycosylation Sites in Proviral DNA at the Intrahost Level. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 199-206.	1.1	10
112	Distinct Profiles of Cytotoxic Granules in Memory CD8 T Cells Correlate with Function, Differentiation Stage, and Antigen Exposure. <i>Journal of Virology</i> , 2009, 83, 2862-2871.	3.4	104
113	IL-2 α and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 758-762.	2.9	211
114	Polyfunctional HCV-specific T α cell responses are associated with effective control of HCV replication. <i>European Journal of Immunology</i> , 2008, 38, 2665-2677.	2.9	138
115	EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. <i>Vaccine</i> , 2008, 26, 3162-3174.	3.8	89
116	EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. <i>Vaccine</i> , 2008, 26, 3153-3161.	3.8	54
117	A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response. <i>Vaccine</i> , 2008, 26, 4006-4014.	3.8	17
118	HIV-specific Immune Response. <i>Advances in Pharmacology</i> , 2008, 56, 75-92.	2.0	10
119	Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. <i>Journal of Experimental Medicine</i> , 2008, 205, 2717-2725.	8.5	153
120	Independent Evolution of Hypervariable Regions of HIV-1 gp120: V4 as a Swarm of N-Linked Glycosylation Variants. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 106-113.	1.1	17
121	An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. <i>Journal of Experimental Medicine</i> , 2008, 205, 63-77.	8.5	273
122	Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. <i>Brain</i> , 2008, 131, 1712-1721.	7.6	150
123	Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 16233-16238.	7.1	118
124	Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure. <i>Aids</i> , 2007, 21, 23-30.	2.2	20
125	Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. <i>Vaccine</i> , 2007, 25, 2120-2127.	3.8	96
126	Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization. <i>European Journal of Immunology</i> , 2007, 37, 1129-1138.	2.9	39

#	ARTICLE	IF	CITATIONS
127	Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response. <i>Journal of Neuroimmunology</i> , 2007, 192, 192-197.	2.3	7
128	Three-Year Immune Reconstitution in PI-Sparing and PI-Containing Antiretroviral Regimens in Advanced HIV-1 Disease. <i>Antiviral Therapy</i> , 2007, 12, 553-558.	1.0	6
129	Clinical studies of experimental vaccines. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 286-293.	3.8	4
130	Functional signatures of protective antiviral T-cell immunity in human virus infections. <i>Immunological Reviews</i> , 2006, 211, 236-254.	6.0	256
131	Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. <i>Nature Reviews Immunology</i> , 2006, 6, 417-423.	22.7	190
132	Standardization of cytokine flow cytometry assays. <i>BMC Immunology</i> , 2005, 6, 13.	2.2	203
133	Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. <i>European Journal of Immunology</i> , 2005, 35, 3493-3504.	2.9	57
134	Understanding what makes a good versus a bad vaccine. <i>European Journal of Immunology</i> , 2005, 35, 2528-2531.	2.9	2
135	HIV-1-specific IFN- γ /IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 7239-7244.	7.1	277
136	Functional Heterogeneity of Memory CD4 T Cell Responses in Different Conditions of Antigen Exposure and Persistence. <i>Journal of Immunology</i> , 2005, 174, 1037-1045.	0.8	271
137	Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. <i>Nature Medicine</i> , 2004, 10, 806-810.	30.7	426
138	Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. <i>European Journal of Immunology</i> , 2004, 34, 3525-3533.	2.9	169
139	Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. <i>Blood</i> , 2004, 103, 966-972.	1.4	345
140	Analysis of HIV-1 and CMV-specific memory CD4 T-cell responses during primary and chronic infection. <i>Blood</i> , 2002, 100, 1381-1387.	1.4	97
141	Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections. <i>European Journal of Immunology</i> , 2002, 32, 3756-3764.	2.9	79
142	Skewed maturation of memory HIV-specific CD8 T lymphocytes. <i>Nature</i> , 2001, 410, 106-111.	27.8	910
143	Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. <i>Aids</i> , 2000, 14, 2257-2263.	2.2	38
144	Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1887-1897.	2.2	64

#	ARTICLE	IF	CITATIONS
145	Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. <i>Nature Medicine</i> , 2000, 6, 762-768.	30.7	192
146	The moving target: mechanisms of HIV persistence during primary infection. <i>Trends in Immunology</i> , 1999, 20, 446-450.	7.5	48
147	Unraveling the strands of HIV's web. <i>Nature Medicine</i> , 1999, 5, 27-28.	30.7	16
148	Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope. <i>European Journal of Immunology</i> , 1999, 29, 3629-3635.	2.9	38
149	Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. <i>Aids</i> , 1999, 13, 1503-1509.	2.2	13
150	CCR2 Polymorphism and HIV Disease. <i>Nature Medicine</i> , 1998, 4, 252-253.	30.7	63
151	Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy. <i>Nature Medicine</i> , 1998, 4, 341-345.	30.7	129
152	Limited CD4+ T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy. <i>Nature Medicine</i> , 1998, 4, 794-801.	30.7	151
153	Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Long-Term Nonprogressive Infection. <i>Journal of Infectious Diseases</i> , 1997, 176, 924-932.	4.0	311
154	Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection. <i>European Journal of Immunology</i> , 1997, 27, 3166-3173.	2.9	43
155	The multi-faceted personality of HIV. <i>Nature Medicine</i> , 1997, 3, 1318-1320.	30.7	10
156	Introduction: Recent advances in the pathogenesis of human immunodeficiency virus infection. <i>Seminars in Immunopathology</i> , 1997, 18, 253-256.	4.0	3
157	Studies in Subjects with Long-Term Nonprogressive Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1995, 332, 209-216.	27.0	717
158	HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. <i>Nature</i> , 1993, 362, 355-358.	27.8	1,837
159	The Immunopathogenesis of Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1993, 328, 327-335.	27.0	1,049
160	A Highly Potent Antibody Effective Against SARS-CoV-2 Variants of Concern. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
161	Case Report: SARS-CoV-2 as an unexpected causal agent of predominant febrile hepatitis. <i>F1000Research</i> , 0, 10, 400.	1.6	1